AffaMed Therapeutics lero yalengeza kuti DEXTENZA yavomerezedwa ku Macau, China kuti ichiritse kutupa kwamaso ndi kupweteka pambuyo pa opaleshoni ya maso. Mu 2020, AffaMed Therapeutics idachita mgwirizano walayisensi ndi Ocular Therapeutix pakupanga ndi kugulitsa kwa DEXTENZA ku Greater China, South Korea, ndi misika ina ya ASEAN. DEXTENZA pano idavomerezedwa ku US kuti azichiza kutupa kwamaso ndi kupweteka pambuyo pa opaleshoni yamaso komanso kuchiza kuyabwa kwamaso komwe kumayenderana ndi matupi awo sagwirizana ndi conjunctivitis.
Dr. Dayao Zhao, yemwe ndi mkulu wa bungwe la AffaMed anati: “Timalimbikitsidwa ndi mfundo za boma la Macau komanso mmene boma la Macau limayendera polembetsa mankhwala ochiritsira atsopano potengera zomwe zayesedwa kwambiri ndi mayeso achipatala a Ocular a FDA. Gulu lathu likukonzekera pulogalamu yokulitsa chizindikiritso chovomerezeka kuti chiphatikizepo chithandizo cha kuyabwa kwamaso komwe kumakhudzana ndi matupi awo sagwirizana ndi conjunctivitis. Tikuyembekezera kukhazikitsa DEXTENZA ndikupereka mankhwalawa kwa odwala ku Macau posachedwa. "
Polandira chivomerezochi, DEXTENZA imakhala yoyamba yotulutsa intracanalicular intracanalicular ku Macau yopereka mlingo wopanda chitetezo wa dexamethasone kwa masiku 30 ndi chithandizo chimodzi.
ZOMWE MUNGACHITE PA NKHANIYI:
- for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis.
- In 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets.
- Polandira chivomerezochi, DEXTENZA imakhala yoyamba yotulutsa intracanalicular intracanalicular ku Macau yopereka mlingo wopanda chitetezo wa dexamethasone kwa masiku 30 ndi chithandizo chimodzi.
